Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder
April 26th, 2024
Here, we present a protocol that investigates the relationship between cognitive symptoms and sleep quality in patients with major depressive disorder. The THINC-integrated tool and polysomnography were used to evaluate cognitive symptoms and sleep quality.
In this study, gold standard polysomnography was used to assess sleep quality and the validated cognitive screening tool was used to evaluate cognitive function in major depressive disorder patients. Thinking to recently developed Chinese version of the cognitive screening tools has been confirmed to be a good tool for evaluation cognitive defects in Chinese patients with major depressive disorder. The current study reveals the close relationship between cognitive symptoms and sleep disorders in major depressive disorder patients.
To begin, collect the participant's demographics and instruct them to complete the Epworth Sleeping Scale. Lead the participant to the sleep monitoring room. Next, connect 15 electrodes of the electroencephalogram according to the International 10-20 system of electrode placement.
Also, connect the two derivations of electrooculogram near the participant's eyes. Three derivations of chin electromyogram, and two derivations of electrocardiogram. To acquire data, start the software by double clicking on device manager.
Double click the room option, add the personal information of the participant and click okay. Click start recording, followed by the calibration button. Instruct the participant to perform according to the step-by-step calibration procedure.
Keep the derivations in the correct position and collect the data for the entire night. On the next day, wake the participant by turning on the light of the sleep monitoring room. For post calibration, click the calibration button and instruct the participant to repeat the step-by-step calibration procedure, then click the close button to stop recording.
After recording, remove all the derivations, avoiding skin damage. Next, start the scoring system by double clicking the ProFusion PSG four button. Select the participant and click the scoring button.
Select the scoring automatically option to score sleep phases and arousals. Click the create button and lay out the results. Review the variables like time in bed, total sleep time, sleep latency, wake after sleep onset, sleep efficiency, and REM latency according to the PSG data and waves.
To begin, explain the procedure to the participants. Then double click the think it button to start the software. Enter the name, age, gender, dominant hand, educational level and location, and click the begin test button.
To evaluate subjective cognitive deficits, guide the patient to complete the perception deficits questionnaire. Read aloud, during the past seven days, how often did you have trouble getting things organized? And instruct the participant to choose one of the five response options.
Read the next question, during the past seven days, how often did you have trouble concentrating on what you were reading? And instruct the participant to choose one of the five response options. Again, read the question, during the past seven days, how often did you forget the date unless you looked it up?
And allow the participant to choose their response. Read the question, during the past seven days, how often did you forget what you talked about after a telephone conversation? And let the participant choose their response.
Finally, read aloud, during the past seven days, how often did you feel like your mind went totally blank? And instruct the participant to choose one of the five response options. Click the okay button to finish the assessment.
Using this protocol, 20 participants were evaluated for cognitive function using cognitive screening scores such as PDQ-5, SPO, SC, CB, and TMT-B.
Overview
This study investigates the relationship between cognitive symptoms and sleep quality in patients with major depressive disorder. Using polysomnography and a validated cognitive screening tool, the research highlights the connection between cognitive deficits and sleep disorders.
Key Study Components
Area of Science
- Neuroscience
- Psychiatry
- Sleep Medicine
Background
- Major depressive disorder often presents with cognitive symptoms.
- Sleep quality is frequently impaired in these patients.
- Understanding the link between cognition and sleep can inform treatment strategies.
- The Chinese version of cognitive screening tools is validated for use in this population.
Purpose of Study
- To assess cognitive function in patients with major depressive disorder.
- To evaluate sleep quality using polysomnography.
- To explore the relationship between cognitive symptoms and sleep disorders.
Methods Used
- Participants' demographics were collected.
- The Epworth Sleeping Scale was administered.
- Polysomnography was conducted with 15 electrodes placed according to the International 10-20 system.
- A validated cognitive screening tool was utilized for assessment.
Main Results
- A close relationship between cognitive symptoms and sleep disorders was revealed.
- The cognitive screening tool effectively identified cognitive defects.
- Polysomnography provided detailed insights into sleep quality.
- Findings support the need for integrated treatment approaches.
Conclusions
- Cognitive symptoms are significantly linked to sleep quality in major depressive disorder.
- Improving sleep may enhance cognitive function in affected patients.
- Further research is warranted to explore therapeutic interventions.
Frequently Asked Questions
Executive Industry Relevance
Quantitative assessment of sleep quality and cognitive symptoms in major depressive disorder (MDD) addresses a critical gap in translational neuroscience and psychiatric drug discovery. Integrating gold standard polysomnography with validated cognitive screening tools enables mechanistic de-risking and supports predictive confidence in target validation for neuropsychiatric portfolios. These insights inform early-stage decision-making and cross-functional prioritization in CNS therapeutic development.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of the mechanistic link between sleep disturbance and cognitive dysfunction in MDD.
- Supports biological de-risking by quantifying associations between objective sleep metrics and cognitive outcomes.
- Facilitates predictive confidence in target selection for neuropsychiatric indications.
Screening & Assay Development
- Provides standardized, reproducible protocols for sleep and cognitive phenotyping in clinical research settings.
- Delivers quantitative outputs (e.g., sleep latency, wake-after-sleep onset, sleep efficiency) for assay development and compound screening.
- Enables reliable evaluation of candidate interventions targeting sleep or cognitive endpoints.
Translational & Preclinical Research
- Aligns clinical cognitive and sleep phenotypes with preclinical model endpoints for translational continuity.
- Supports risk-adjusted advancement decisions by linking human biomarker data to disease-relevant systems.
- Provides a framework for integrating cognitive and sleep metrics into early proof-of-concept studies.
Pipeline & Workflow Integration
This protocol positions objective sleep and cognitive assessments at the intersection of early discovery, lead identification, and translational research in CNS drug development.
- Discovery Biology: Quantifies the relationship between sleep architecture and cognitive impairment, informing hypothesis testing and pathway clarification.
- Screening: Standardizes measurement of sleep and cognitive endpoints for reproducible cross-study comparisons.
- Analytics: Generates quantitative readouts (e.g., sleep efficiency, cognitive scores) to support statistical analysis and condition comparison.
- Translational Research: Bridges clinical and preclinical research by aligning human phenotypes with model system outputs.
- Enterprise Reuse: Establishes a reusable protocol for future CNS and psychiatric research pipelines.
Operational & Enterprise Impact
- Scientific Value: Enhances predictive confidence and reduces mechanistic ambiguity in neuropsychiatric target validation.
- Operational Value: Delivers standardized, scalable, and reproducible assessment workflows for sleep and cognition.
- Strategic Value: Informs go/no-go decisions and capital allocation by linking objective biomarkers to clinical endpoints.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of CNS therapeutic candidates.
Implementation Considerations
- Requires expertise in polysomnography and cognitive assessment administration.
- Demands access to specialized instrumentation and validated analytical software.
- Necessitates cross-team standardization for data collection and interpretation.
- May require adaptation for use in diverse patient populations or model systems.
- Dependent on participant compliance and high-quality data acquisition.
